NCT05121571View on ClinicalTrials.gov

The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

NACompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

April 21, 2016

Primary Completion Date

December 12, 2018

Study Completion Date

May 1, 2021

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE

HAIC

administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

DRUG

Sorafenib

sorafenib 400mg bid

Trial Locations (1)

510060

Cancer Center Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT05121571 - The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study | Biotech Hunter | Biotech Hunter